Skip to content

Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma

Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07180992
Acronym
MONOMM
Enrollment
25
Registered
2025-09-18
Start date
2025-07-16
Completion date
2028-09-30
Last updated
2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CART Cells, Monocytes, Multiple Myeloma

Keywords

Multiple myeloma, Monocytes, CART cells, Microenvironment

Brief summary

Tumoral micro-environment in malignant haematological diseases, notably in multiple myeloma, is active on plasma cells survival and proliferation. Monocytosis and monocytes typing are described in multiple myeloma response as factors on proliferation and cell death evasion. CART cells have improved multiple myeloma care in last 5 years, nethertheless, early relapse occur and we must identify predictor factors of better response. The aim of this study is to analyze basic level and phenotyping of monocytes before and after CART cells infusion and study their impact on multiple myeloma response

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 18 years old * Treated for a multiple myeloma * CART cells treatment proposed * Affiliated to social security system * Agreed to participate to the study

Design outcomes

Primary

MeasureTime frame
overall response rateday 1

Secondary

MeasureTime frame
Progression free survival3 years
Overall survival3 years
time to next treatment3 years

Countries

France

Contacts

Primary ContactLydia Montes, MD
Montes.lydia@chu-amiens.fr33+322088371

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026